SCYNEXIS (LTS:0L49) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L49 SCYNEXIS Inc LTS:0L49
45 GF Score
Price $5.27
GF Value $17.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0L49 vs IXHL, ETST, INIS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Short Interest distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Short Interest falls into.


LTS:0L49
45GF Score
SCYNEXIS Inc LTS:0L49
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SCYNEXIS (LTS:0L49) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.27 is trading 70.6% below its estimated GF Value™ of $17.91. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for LTS:0L49:

  • Short Interest:
  • GF Value™: $17.91 vs. price of $5.27 (70.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0L49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
45GF Score

Get the complete analysis for LTS:0L49

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$17.91
GF Value